Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This study mainly to observe the anti angiogenic drugs Endostatin (Endostar) combined with
vinorelbine and Cisplatin (NP) as neoadjuvant therapy in patients with non small cell lung
cancer clinical efficiency and safety. Through anti angiogenesis therapy combined with
neoadjuvant chemotherapy improve the treatment of neoadjuvant therapy in tumor response rate
and the rate of resection, At the same time, the study before and after the anti angiogenesis
therapy in patients with peripheral blood circulation endothelial cells(CECs), levels of
Endothelial progenitor cells（EPC）, micro vascular density（MVD） and vascular endothelial
growth factor(VEGF) expression level, to understanding the correlation between the clinical
efficacy of anti angiogenesis therapy combined with chemotherapy and the change of all these
markers. In order to find the reference basis for the prediction of the effect of curative
effect. The changes of blood volume, blood flow and vascular permeability of the lung cancer
before and after treatment with CT perfusion imaging are studied.
Phase:
Phase 4
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital